Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drugstore.com earnings

This article was originally published in The Tan Sheet

Executive Summary

OTC net sales advanced 18.3 percent to $234.3 million in 2007, "in line with e-commerce trends, but below our expectations due to increased marketing costs in paid search and portals," the e-commerce marketer announces during a Feb. 6 analyst meeting. Gross profit for OTCs during the year advanced 19.8 percent to $69.8 million. For the fourth quarter, OTC revenues were up 17.4 percent to $65.8 million, while gross profit for the period advanced 31.6 percent to $20.5 million. Drugstore.com's net sales for the full year grew 7.2 percent to $445.7 million, though the firm experienced a $9 million loss during the quarter, an improvement over a loss of $13 million last year. In 2008, the company plans to fuel top-line revenue growth in part by driving OTC sales up 20 percent year-over-year, the company says...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel